Insulet is trading 4.90% down at $156.93 amid the broad November 5, 2026 market selloff, with major U.S. indexes sharply lower and technology weakness weighing on equities.

  • November 4 earnings beat estimates, with revenue of $842 million and adjusted EPS of $1.99.
  • Insulet raised its 2026 revenue outlook and authorized a $1 billion buyback, but those earlier positives have not prevented today’s decline.